[일반원칙]경구용 뇌대사개선제(Neuroprotective agents)

[안선생]

각 약제의 허가사항 범위 내에서 아래와 같이 투여 시 요양급여 인정하며, 허가사항 범위이지만 동 인정기준 이외에 투여한 경우에는 약값전액을 환자가 부담토록 함.[고시 제2012-105호]
- 아     래 -
가. 경구용 뇌대사개선제※ 중 1종만 요양급여 인정함을 원칙으로 함.
나. 개별고시가 있는 약제는 해당 고시기준을 따름.

※ 대상약제: Acetyl L-carnitine HCL, Citicoline, Oxiracetam, Choline alfoscerate, Ifenprodil tartrate, Thymoxamine HCL, Nicergoline, Ibudilast

* 시행일 2012.11.1.
* 신설사유: 뇌대사개선제에 해당하는 성분을 명확히 하였으며, 동 제제는 보조적인 치료제로 병용투여에 대한 근거가 불명확함에 따라 대상약제 중 1종만 인정함
* 관련근거:  ·뇌졸중진료지침: 뇌졸중임상연구센터
 ·Guidelines for the early management of adults with ischemic stroke: AHA/ASA
 ·European Stroke Initiative Recommendations for Stroke Management - Update 2003: The European Stroke Initiative Executive Committee and the EUSI Writing Committee
 ·Italian Guidelines for Stroke Prevention and Management
 ·Acute medical and surgical management. In: Clinical guidelines for stroke management 2010: Melbourne (Australia): National Stroke Foundation(2010)
 ·Clinical Guidelines for Acute Stroke Management: Australian National Stroke Foundation 2007
 ·Rehabilitation. In: Clinical guidelines for stroke management 2010: National Stroke Foundation 2010
 ·New Zealand Clinical Guidelines for Stroke Management 2010: Stroke Foundation of New Zealand(2010)
 ·Stroke and transient ischaemic attacks. Assessment, investigation, immediate management and secondary prevention: Singapore Ministry of Health(2009)
 ·Japanese Guidelines for the Management of Stroke 2009: 일본신경치료학회(2009)
 ·Textbook of natural medicine 2006, 1466P
 ·Cochrane(2008): Acetyl-l-carnitine for dementia
 ·SIGN(2006): Management of patients with dementia. A national clinical guideline
 ·Acetyl-L-carnitine(ALC) treatment in elderly patients with fatigu
·A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery. Drug Dev Res 1988;14(3-4):217-4.
·A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.Gllai V, Mazzotta G, Del Gatto F, Montesi S, Mazzetti A, Dominici P, Della Monica A. Acta Neurol (Napoli). 1991 Feb;13(1):1-12
·Oxiracetam in dementia: a double-blind, placebo-controlled study. Acta Neurol Scand. 1992 Sep;86(3):237-41.
·Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.  Neuropsychobiology. 1989;21(3):141-5.
·Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. Dysken MW, Katz R, Stallone F, Kuskowski M. J Neuropsychiatry Clin. 1989 Summer;1(3):249-52.
· Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Neuropsychobiology. 1992;25(1):24-8.